Immunotherapy Continues to Redefine Treamtent Considerations in Advanced/Recurrent Endometrial Cancer OncLive
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial Nature.com
Endometriosis affects 10-15% of people assigned female at birth and can cause chronic pelvic pain and impair many domains of quality of life, such as fertility, mood and bladder, bowel …
Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis BioMed Central
Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis bmcwomenshealth.biomedcentral.com
Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial Nature.com
Endometriosis (EMs) is a common condition that causes dysmenorrhea, chronic pelvic pain, and infertility, affecting millions of women worldwide. Despite the use of assisted reproductive technology, EMs patients often experience …
Endometriosis affects approximately 10% of premenopausal women, with urinary tract involvement in 1% of cases. Ureteric endometriosis is a rare, typically asymptomatic, cause of obstructive renal failure. We present the …
The uterus is a complex organ that requires precise signaling networks to mediate functions necessary for homeostasis and reproductive processes. The transforming growth factor β (TGFβ) superfamily regulates integral signaling …
Endometriosis, while prevalent, can manifest in extra-pelvic locations with varying degrees of rarity, but reports of multiple extra-pelvic sites within a patient are extremely rare. We report a unique case …